Intervacc Past Earnings Performance
Past criteria checks 0/6
Intervacc's earnings have been declining at an average annual rate of -33.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 2.5% per year.
Key information
-33.5%
Earnings growth rate
-21.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -2.5% |
| Return on equity | -42.9% |
| Net Margin | -832.8% |
| Next Earnings Update | 13 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Intervacc makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 9 | -77 | 57 | 0 |
| 30 Jun 24 | 10 | -103 | 60 | 0 |
| 31 Mar 24 | 9 | -103 | 58 | 0 |
| 31 Dec 23 | 8 | -103 | 56 | 0 |
| 30 Sep 23 | 10 | -106 | 56 | 0 |
| 30 Jun 23 | 10 | -73 | 50 | 0 |
| 31 Mar 23 | 12 | -71 | 49 | 0 |
| 31 Dec 22 | 12 | -64 | 46 | 0 |
| 30 Sep 22 | 10 | -50 | 40 | 0 |
| 30 Jun 22 | 10 | -44 | 38 | 0 |
| 31 Mar 22 | 9 | -34 | 34 | 0 |
| 31 Dec 21 | 9 | -29 | 32 | 0 |
| 30 Sep 21 | 9 | -28 | 31 | 0 |
| 30 Jun 21 | 8 | -26 | 29 | 0 |
| 31 Mar 21 | 7 | -26 | 27 | 0 |
| 31 Dec 20 | 7 | -26 | 27 | 0 |
| 30 Sep 20 | 7 | -26 | 27 | 0 |
| 30 Jun 20 | 8 | -26 | 27 | 0 |
| 31 Mar 20 | 9 | -29 | 27 | 0 |
| 31 Dec 19 | 14 | -28 | 27 | 0 |
| 30 Sep 19 | 16 | -27 | 26 | 0 |
| 30 Jun 19 | 26 | -26 | 26 | 0 |
| 31 Mar 19 | 41 | -29 | 24 | 0 |
| 31 Dec 18 | 38 | -27 | 23 | 0 |
| 30 Sep 18 | 38 | -27 | 22 | 0 |
| 30 Jun 18 | 38 | -24 | 21 | 0 |
| 31 Mar 18 | 43 | -16 | 23 | 0 |
| 31 Dec 17 | 50 | -13 | 22 | 0 |
| 30 Sep 17 | 52 | -11 | 21 | 0 |
| 30 Jun 17 | 56 | -9 | 20 | 0 |
| 31 Mar 17 | 63 | -6 | 18 | 0 |
| 31 Dec 16 | 58 | -7 | 18 | 0 |
| 31 Dec 15 | 65 | 0 | 20 | 0 |
| 31 Dec 14 | 80 | 9 | 20 | 0 |
| 31 Dec 13 | 1 | -2 | 3 | 0 |
Quality Earnings: 2E9 is currently unprofitable.
Growing Profit Margin: 2E9 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2E9 is unprofitable, and losses have increased over the past 5 years at a rate of 33.5% per year.
Accelerating Growth: Unable to compare 2E9's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2E9 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 2E9 has a negative Return on Equity (-42.87%), as it is currently unprofitable.